Another Victory Of Russian Science: Vector Claimed Successful Trial Of HIV Vaccine

Support SouthFront

Another Victory Of Russian Science: Vector Claimed Successful Trial Of HIV Vaccine

Illustrative image

The human immunodeficiency virus (HIV) vaccine developed by the Vector Research Center of Rospotrebnadzor is capable to produce antibodies to the virus. This was confirmed during the first phase of clinical trials in 100% of volunteers, Vector claimed on December 18.

“HIV-specific antibodies and cytotoxic T lymphocytes were identified after double vaccination in 100% of the volunteers; antibodies, masked viruses, that neutralize HIV were traced in 80% of cases,” – Vector said.

The Center clarified that the first phase of clinical studies of the “CombiHIVvac” vaccine was conducted in 2011, and they confirmed that “the vaccine is safe, does not cause any adverse reaction and induces an HIV-specific humoral and cellular response.”

At the moment, Vector has developed an improved version of the “CombiHIVvac – Novo” vaccine on the basis of “CombiHIVvac”. The effectiveness of the HIV vaccine can be determined in further clinical studies.

For the first time, the head of Rospotrebnadzor Anna Popova announced that an HIV vaccine had been developed in Russia on December 1.

According to the Russian State Drug Tariff, permission for clinical trials of the “CombiHIVvac” was issued in 2013, and they will continue until the end of 2021.

Tests are carried out on 240 volunteers in two medical organizations – the Federal Medical-Biological Agency’s medical unit and the infectious diseases center, both institutions are located in the Novosibirsk region.

“Vector” reported that the immunoprophylactic HIV/AIDS vaccine contained small fragments of the main viral proteins that are highly conservative for the three HIV-1 subtypes A, B, and C.

“The advantage of such vaccines is that they include only fragments of viral proteins necessary for the formation of specific immunity, do not contain in their composition full – size structures of the virus in their composition, which can be factors of pathogenicity and/or can inhibit the formation of protective immunity or stimulate the development of autoimmune reactions,” the research center said.

The developers note that the activity of antibodies in the new version of the “Vector” HIV vaccine is ten times higher than in the original one.

“To complete the development of the “CombiHIVvac” vaccine, it is necessary to conduct clinical trials and register the vaccine in the Russian Federation,” Vector said.


Support SouthFront